TESARO, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-03-01
- Employees
- 715
- Market Cap
- -
- Website
- http://tesarobio.com
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05751629
- Locations
- 🇺🇸
GSK Investigational Site, Oklahoma City, Oklahoma, United States
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 785
- Registration Number
- NCT03981796
- Locations
- 🇬🇧
GSK Investigational Site, Truro, United Kingdom
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03955471
- Locations
- 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 1402
- Registration Number
- NCT03602859
- Locations
- 🇬🇧
GSK Investigational Site, Wirral, United Kingdom
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT03574779
- Locations
- 🇹🇷
GSK Investigational Site, Antalya, Turkey
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03359850
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03329937
- Locations
- 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT03329001
- Locations
- 🇺🇸
GSK Investigational Site, San Marcos, Texas, United States
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03326193
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03308942
- Locations
- 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States
© Copyright 2024. All Rights Reserved by MedPath